'Covaxin provides 65.2% protection against Delta variant'
Phase-III trials of Covaxin, made by Hyderabad's Bharat Biotech showed it was 93.4% effective against severe symptomatic Covid-19, the firm said on Saturday. The data demonstrated 65.2% protection against the Delta variant, first identified in India. The Delta variant had led to a surge in infections in April and May, and the world's highest daily death tolls.
admin 
Phase-III trials of Covaxin, made by Hyderabad's Bharat Biotech showed it was 93.4% effective against severe symptomatic Covid-19, the firm said on Saturday. The data demonstrated 65.2% protection against the Delta variant, first identified in India. The Delta variant had led to a surge in infections in April and May, and the world's highest daily death tolls.
